دورية أكاديمية
أعرض في EDS

Injection Site Reaction to Various Insulins as Type III Allergy With Urticarial Vasculitis in a Patient With Type I Diabetes Mellitus.

التفاصيل البيبلوغرافية
العنوان: Injection Site Reaction to Various Insulins as Type III Allergy With Urticarial Vasculitis in a Patient With Type I Diabetes Mellitus.
المؤلفون: Müller CSL; Medical Supply Center for Histology, Cytology, and Molecular Diagnostics Trier, Wissenschaftspark Trier, Germany., Bourg C; Saarland University Hospital, Clinic for Dermatology, Venereology and Allergology, Homburg/Saar, Germany; and., Schweitzer LF; Saarland University Hospital, Clinic for Dermatology, Venereology and Allergology, Homburg/Saar, Germany; and., Friesenhahn-Ochs B; Saarland University Hospital, Clinic for Internal Medicine II, Homburg/Saar, Germany., Pföhler C; Saarland University Hospital, Clinic for Dermatology, Venereology and Allergology, Homburg/Saar, Germany; and.
المصدر: The American Journal of dermatopathology [Am J Dermatopathol] 2023 Feb 01; Vol. 45 (2), pp. 86-89. Date of Electronic Publication: 2022 Dec 07.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7911005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-0311 (Electronic) Linking ISSN: 01931091 NLM ISO Abbreviation: Am J Dermatopathol Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York, Masson Publishing USA.
مواضيع طبية MeSH: Diabetes Mellitus, Type 1*/drug therapy , Drug Hypersensitivity* , Urticaria*/chemically induced , Immune Complex Diseases*, Humans ; Young Adult ; Adult ; Middle Aged ; Injection Site Reaction/etiology ; Insulin/adverse effects
مستخلص: Abstract: Injection site reactions are defined as skin reactions at the injection site to drugs administered subcutaneously. Pathophysiologically, these reactions are based on different immunological mechanisms. We report the case of a 49-year-old patient with type 1 diabetes mellitus (first diagnosis in 1994 at the age of 23 years). Continuous subcutaneous insulin infusion using an insulin pump has been used for many years. The patient presented to the department of dermatology with progressive symptoms in the area of the insulin injection sites on the lower abdomen, accompanied by pain, burning, erythema, tenderness, and the formation of subcutaneous nodules. Previous attempts to use different insulins and to change the injection sites did not improve his symptoms. Furthermore, the symptoms appeared within hours after the insulin pump was attached, so that the injection site has to be changed as soon as every 48 hours. No anaphylactic shock was reported at any time. Multiple histological specimens were obtained from an older lesion on the abdomen as well as from test sites after standard allergological tests (prick and intradermal tests) of various insulins. Histologically, these biopsies showed the image of an extensive deep-reaching small vessel vasculitis with the aspect of an urticarial vasculitis and confirmed the diagnosis of an injection-site reaction that can be characterized as a type III hypersensitivity reaction.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Grace E, Goldblum O, Renda L, et al. Injection site reactions in the federal adverse event reporting system (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. Dermatol Ther (Heidelb). 2020;10:99–106.
Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32:e12817.
Prieto-Barrios M, Rodriguez-Peralto JL, Vico-Alonso C, et al. Injection-site reaction to ixekizumab histologically mimicking lupus tumidus: report of two cases. Indian J Dermatol Venereol Leprol. 2018;84:610–613.
Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein. Arch Dermatol. 2001;137:893–899.
Ramot Y, Kannan K, Reddy S, et al. Acute histopathologic findings related to needle puncture trauma during subcutaneous injection in the sprague-dawley rat model. Toxicol Pathol. 2019;47:93–96.
Maggi P, Ladisa N, Cinori E, et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53:678–681.
Maggi P, Filotico R, Bonora S, et al. Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug? Clin Drug Invest. 2008;28:305–311.
Murray BR, Jewell JR, Jackson KJ, et al. Type III hypersensitivity reaction to subcutaneous insulin preparations in a type 1 diabetic. J Gen Intern Med. 2017;32:841–845.
Silva ME, Mendes MJ, Ursich MJ, et al. Human insulin allergy-immediate and late-type III reactions in a long-standing IDDM patient. Diabetes Res Clin Pract. 1997;36:67–70.
Marusic S, Vlahovic-Palcevski V, Ljubanovic D. Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes. Int J Clin Pharmacol Ther. 2009;47:603–605.
Darmon P, Castera V, Koeppel MC, et al. Type III allergy to insulin detemir. Diabetes Care. 2005;28:2980.
Mandrup-Poulsen T, Molvig J, Pildal J, et al. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia. Diabetes Care. 2002;25:242–243.
Rachid B, Rabelo-Santos M, Mansour E, et al. Type III hypersensitivity to insulin leading to leukocytoclastic vasculitis. Diabetes Res Clin Pract. 2010;89:e39–e40.
van der Bent S, Oyen E, Rustemeyer T, et al. Histopathology of red tattoo reactions. Am J Dermatopathol. 2021;43:331–337.
المشرفين على المادة: 0 (Insulin)
تواريخ الأحداث: Date Created: 20230120 Date Completed: 20230124 Latest Revision: 20230201
رمز التحديث: 20240628
DOI: 10.1097/DAD.0000000000002356
PMID: 36669070
قاعدة البيانات: MEDLINE
الوصف
تدمد:1533-0311
DOI:10.1097/DAD.0000000000002356